Noah Goodman, serving as the Chief Business Officer at Kymera Therapeutics, Inc. (NASDAQ:KYMR), executed a sale of 2,500 shares of the company’s common stock on June 22, 2026. The transaction resulted in a total value of $247,500, with shares sold at a price of $99.00 per share. This activity took place while the stock was trading at $99.45, a level near its 52-week high of $105. The stock has experienced a 117% gain over the past year. According to InvestingPro analysis, the stock appears overvalued at current levels relative to its Fair Value, placing it among companies on the Most Overvalued list.
The sale was executed pursuant to a Rule 10b5-1 trading plan that Goodman adopted on December 10, 2025. Following the sale, Goodman directly holds 50,195.438 shares of Kymera Therapeutics common stock. This transaction followed the acquisition of 2,500 shares of common stock on the same day, also under the Rule 10b5-1 trading plan. These shares were acquired at a price of $21.05 per share, totaling $52,625. This acquisition was a result of exercising stock options. The stock options, which give the right to buy common stock at $21.05 per share, had 25% of their underlying shares vest on April 8, 2026, with the remainder vesting in thirty-six equal monthly installments thereafter, contingent on continued employment. After the option exercise, Goodman holds 95,000 derivative shares.
In other recent news, Kymera Therapeutics has been the focus of several significant developments. The company received a $20 million milestone payment from Sanofi following the dosing of the first participant in a Phase 1 trial for KT-485, an oral IRAK4 degrader. Additionally, Kymera presented promising Phase 1 data for KT-621 in healthy Japanese adults, demonstrating rapid absorption and a favorable safety profile. Brookline Capital Markets raised its price target for Kymera to $97, maintaining a Buy rating due to new preclinical data showing KT-579’s disease-modifying activity in lupus models. Truist Securities reiterated a Buy rating and a $116 price target for Kymera after AbbVie’s acquisition of Apogee, seeing it as a positive indicator for the immunology landscape. In leadership news, Kymera appointed Penny Carlson as Senior Vice President of Development Operations, bringing over 20 years of biopharmaceutical experience. These developments highlight Kymera’s ongoing progress in clinical trials and strategic leadership.